Company / EPS (Diluted)
Crinetics Pharmaceuticals, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$4.95
FY2025
5-year range
-$4.95 / -$2.80
FY2021-FY2025
Trend
-34.1%
vs FY2024
Sector context
#174 of 204
Health Care
What the data says
Crinetics Pharmaceuticals, Inc.'s eps (diluted) of $-4.95 is lower than 85% of companies in the Health Care sector (FY2025). Declined from $-3.69 to $-4.95 over the past 2 years.
Based on SEC 10-K filings.
-4.95 in FY2025.
Declined from $-3.69 to $-4.95 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 204This company -$4.95 Sector average -$0.89
▼
-458.5% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 34.1% year-over-year.
- Ranks #174 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2020.
- Lowest eps (diluted) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.95 | -34.1% |
| FY2024 | -$3.69 | +0.0% |
| FY2023 | -$3.69 | -17.1% |
| FY2022 | -$3.15 | -12.5% |
| FY2021 | -$2.80 | -25.6% |
| FY2020 | -$2.23 | +66.6% |
| FY2019 | -$6.68 | -12.1% |
| FY2018 | -$5.96 | - |
| FY2017 | - | - |
| FY2016 | -$5.96 | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026